Can  ||| S:0 E:4 ||| MD
anaesthetic  ||| S:4 E:16 ||| VB
and  ||| S:16 E:20 ||| CC
analgesic  ||| S:20 E:30 ||| JJ
techniques  ||| S:30 E:41 ||| NNS
affect  ||| S:41 E:48 ||| VBP
cancer  ||| S:48 E:55 ||| NN
recurrence  ||| S:55 E:66 ||| NN
or  ||| S:66 E:69 ||| CC
metastasis ||| S:69 E:79 ||| NN
?  ||| S:79 E:81 ||| .
Cancer  ||| S:81 E:88 ||| NNP
is  ||| S:88 E:91 ||| VBZ
a  ||| S:91 E:93 ||| DT
leading  ||| S:93 E:101 ||| JJ
cause  ||| S:101 E:107 ||| NN
of  ||| S:107 E:110 ||| IN
morbidity  ||| S:110 E:120 ||| NN
and  ||| S:120 E:124 ||| CC
mortality  ||| S:124 E:134 ||| NN
worldwide  ||| S:134 E:144 ||| NNS
and  ||| S:144 E:148 ||| CC
the  ||| S:148 E:152 ||| DT
ratio  ||| S:152 E:158 ||| NN
of  ||| S:158 E:161 ||| IN
incidence  ||| S:161 E:171 ||| NN
is  ||| S:171 E:174 ||| VBZ
increasing ||| S:174 E:184 ||| VBG
.  ||| S:184 E:186 ||| .
Mortality  ||| S:186 E:196 ||| NN
usually  ||| S:196 E:204 ||| RB
results  ||| S:204 E:212 ||| NNS
from  ||| S:212 E:217 ||| IN
recurrence  ||| S:217 E:228 ||| NN
or  ||| S:228 E:231 ||| CC
metastases ||| S:231 E:241 ||| NN
.  ||| S:241 E:243 ||| .
Surgical  ||| S:243 E:252 ||| JJ
removal  ||| S:252 E:260 ||| NN
of  ||| S:260 E:263 ||| IN
the  ||| S:263 E:267 ||| DT
primary  ||| S:267 E:275 ||| JJ
tumour  ||| S:275 E:282 ||| NN
is  ||| S:282 E:285 ||| VBZ
the  ||| S:285 E:289 ||| DT
mainstay  ||| S:289 E:298 ||| NN
of  ||| S:298 E:301 ||| IN
treatment ||| S:301 E:310 ||| NN
,  ||| S:310 E:312 ||| ,
but  ||| S:312 E:316 ||| CC
this  ||| S:316 E:321 ||| DT
is  ||| S:321 E:324 ||| VBZ
associated  ||| S:324 E:335 ||| VBN
with  ||| S:335 E:340 ||| IN
inadvertent  ||| S:340 E:352 ||| JJ
dispersal  ||| S:352 E:362 ||| NN
of  ||| S:362 E:365 ||| IN
neoplastic  ||| S:365 E:376 ||| JJ
cells  ||| S:376 E:382 ||| NNS
into  ||| S:382 E:387 ||| IN
the  ||| S:387 E:391 ||| DT
blood  ||| S:391 E:397 ||| NN
and  ||| S:397 E:401 ||| CC
lymphatic  ||| S:401 E:411 ||| JJ
systems ||| S:411 E:418 ||| NNS
.  ||| S:418 E:420 ||| .
The  ||| S:420 E:424 ||| DT
fate  ||| S:424 E:429 ||| NN
of  ||| S:429 E:432 ||| IN
the  ||| S:432 E:436 ||| DT
dispersed  ||| S:436 E:446 ||| JJ
cells  ||| S:446 E:452 ||| NNS
depends  ||| S:452 E:460 ||| VBZ
on  ||| S:460 E:463 ||| IN
the  ||| S:463 E:467 ||| DT
balance  ||| S:467 E:475 ||| NN
of  ||| S:475 E:478 ||| IN
perioperative  ||| S:478 E:492 ||| JJ
factors  ||| S:492 E:500 ||| NNS
promoting  ||| S:500 E:510 ||| VBG
tumour  ||| S:510 E:517 ||| JJ
survival  ||| S:517 E:526 ||| NN
and  ||| S:526 E:530 ||| CC
growth  ||| S:530 E:537 ||| NN
( ||| S:537 E:538 ||| -LRB-
including  ||| S:538 E:548 ||| FW
surgery  ||| S:548 E:556 ||| FW
per  ||| S:556 E:560 ||| FW
se ||| S:560 E:562 ||| FW
,  ||| S:562 E:564 ||| ,
many  ||| S:564 E:569 ||| JJ
anaesthetics  ||| S:569 E:582 ||| FW
per  ||| S:582 E:586 ||| FW
se ||| S:586 E:588 ||| FW
,  ||| S:588 E:590 ||| ,
acute  ||| S:590 E:596 ||| JJ
postoperative  ||| S:596 E:610 ||| JJ
pain ||| S:610 E:614 ||| NN
,  ||| S:614 E:616 ||| ,
and  ||| S:616 E:620 ||| CC
opioid  ||| S:620 E:627 ||| JJ
analgesics ||| S:627 E:637 ||| NN
)  ||| S:637 E:639 ||| -RRB-
together  ||| S:639 E:648 ||| RB
with  ||| S:648 E:653 ||| IN
the  ||| S:653 E:657 ||| DT
perioperative  ||| S:657 E:671 ||| JJ
immune  ||| S:671 E:678 ||| JJ
status  ||| S:678 E:685 ||| NN
of  ||| S:685 E:688 ||| IN
the  ||| S:688 E:692 ||| DT
patient ||| S:692 E:699 ||| NN
.  ||| S:699 E:701 ||| .
Available  ||| S:701 E:711 ||| JJ
evidence  ||| S:711 E:720 ||| NN
from  ||| S:720 E:725 ||| IN
experimental  ||| S:725 E:738 ||| JJ
cell  ||| S:738 E:743 ||| NN
culture  ||| S:743 E:751 ||| NN
and  ||| S:751 E:755 ||| CC
live  ||| S:755 E:760 ||| JJ
animal  ||| S:760 E:767 ||| NN
data  ||| S:767 E:772 ||| NNS
on  ||| S:772 E:775 ||| IN
these  ||| S:775 E:781 ||| DT
factors  ||| S:781 E:789 ||| NNS
are  ||| S:789 E:793 ||| VBP
summarized ||| S:793 E:803 ||| VBN
,  ||| S:803 E:805 ||| ,
together  ||| S:805 E:814 ||| RB
with  ||| S:814 E:819 ||| IN
clinical  ||| S:819 E:828 ||| JJ
evidence  ||| S:828 E:837 ||| NN
from  ||| S:837 E:842 ||| IN
retrospective  ||| S:842 E:856 ||| JJ
studies ||| S:856 E:863 ||| NNS
.  ||| S:863 E:865 ||| .
Taken  ||| S:865 E:871 ||| VBN
together ||| S:871 E:879 ||| RB
,  ||| S:879 E:881 ||| ,
current  ||| S:881 E:889 ||| JJ
data  ||| S:889 E:894 ||| NNS
are  ||| S:894 E:898 ||| VBP
sufficient  ||| S:898 E:909 ||| JJ
only  ||| S:909 E:914 ||| JJ
to  ||| S:914 E:917 ||| TO
generate  ||| S:917 E:926 ||| VB
a  ||| S:926 E:928 ||| DT
hypothesis  ||| S:928 E:939 ||| NN
that  ||| S:939 E:944 ||| IN
an  ||| S:944 E:947 ||| DT
anaesthetic  ||| S:947 E:959 ||| JJ
technique  ||| S:959 E:969 ||| NN
during  ||| S:969 E:976 ||| IN
primary  ||| S:976 E:984 ||| JJ
cancer  ||| S:984 E:991 ||| NN
surgery  ||| S:991 E:999 ||| NN
could  ||| S:999 E:1005 ||| MD
affect  ||| S:1005 E:1012 ||| VB
recurrence  ||| S:1012 E:1023 ||| NN
or  ||| S:1023 E:1026 ||| CC
metastases ||| S:1026 E:1036 ||| NN
,  ||| S:1036 E:1038 ||| ,
but  ||| S:1038 E:1042 ||| CC
a  ||| S:1042 E:1044 ||| DT
causal  ||| S:1044 E:1051 ||| JJ
link  ||| S:1051 E:1056 ||| NN
can  ||| S:1056 E:1060 ||| MD
only  ||| S:1060 E:1065 ||| RB
be  ||| S:1065 E:1068 ||| VB
proved  ||| S:1068 E:1075 ||| VBN
by  ||| S:1075 E:1078 ||| IN
prospective ||| S:1078 E:1089 ||| JJ
,  ||| S:1089 E:1091 ||| ,
randomized ||| S:1091 E:1101 ||| NN
,  ||| S:1101 E:1103 ||| ,
clinical  ||| S:1103 E:1112 ||| JJ
trials ||| S:1112 E:1118 ||| NNS
.  ||| S:1118 E:1120 ||| .
Many  ||| S:1120 E:1125 ||| JJ
are  ||| S:1125 E:1129 ||| VBP
ongoing ||| S:1129 E:1136 ||| JJ
,  ||| S:1136 E:1138 ||| ,
but  ||| S:1138 E:1142 ||| CC
definitive  ||| S:1142 E:1153 ||| JJ
results  ||| S:1153 E:1161 ||| NNS
might  ||| S:1161 E:1167 ||| MD
not  ||| S:1167 E:1171 ||| RB
emerge  ||| S:1171 E:1178 ||| VB
for  ||| S:1178 E:1182 ||| IN
a  ||| S:1182 E:1184 ||| DT
further  ||| S:1184 E:1192 ||| JJ
5  ||| S:1192 E:1194 ||| CD
yr  ||| S:1194 E:1197 ||| NNS
or  ||| S:1197 E:1200 ||| CC
longer ||| S:1200 E:1206 ||| RBR
.  ||| S:1206 E:1208 ||| .
Meanwhile ||| S:1208 E:1217 ||| RB
,  ||| S:1217 E:1219 ||| ,
there  ||| S:1219 E:1225 ||| EX
is  ||| S:1225 E:1228 ||| VBZ
no  ||| S:1228 E:1231 ||| DT
hard  ||| S:1231 E:1236 ||| JJ
evidence  ||| S:1236 E:1245 ||| NN
to  ||| S:1245 E:1248 ||| TO
support  ||| S:1248 E:1256 ||| VB
altering  ||| S:1256 E:1265 ||| VBG
anaesthetic  ||| S:1265 E:1277 ||| JJ
technique  ||| S:1277 E:1287 ||| NN
in  ||| S:1287 E:1290 ||| IN
cancer  ||| S:1290 E:1297 ||| NN
patients ||| S:1297 E:1305 ||| NNS
,  ||| S:1305 E:1307 ||| ,
pending  ||| S:1307 E:1315 ||| VBG
the  ||| S:1315 E:1319 ||| DT
outcome  ||| S:1319 E:1327 ||| NN
of  ||| S:1327 E:1330 ||| IN
the  ||| S:1330 E:1334 ||| DT
ongoing  ||| S:1334 E:1342 ||| JJ
clinical  ||| S:1342 E:1351 ||| JJ
trials ||| S:1351 E:1357 ||| NNS
.  ||| S:1357 E:1359 ||| .
